[go: up one dir, main page]

MXPA02009043A - Composiciones que comprenden bloqueadores de la transferencia de la celula l-dopa renal para el tratamiento de la enfermedad de parkinson. - Google Patents

Composiciones que comprenden bloqueadores de la transferencia de la celula l-dopa renal para el tratamiento de la enfermedad de parkinson.

Info

Publication number
MXPA02009043A
MXPA02009043A MXPA02009043A MXPA02009043A MXPA02009043A MX PA02009043 A MXPA02009043 A MX PA02009043A MX PA02009043 A MXPA02009043 A MX PA02009043A MX PA02009043 A MXPA02009043 A MX PA02009043A MX PA02009043 A MXPA02009043 A MX PA02009043A
Authority
MX
Mexico
Prior art keywords
dopa
renal cell
parkinson
treatment
disease
Prior art date
Application number
MXPA02009043A
Other languages
English (en)
Inventor
Da Silva Patricio Soares
Original Assignee
Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portela & Ca Sa filed Critical Portela & Ca Sa
Publication of MXPA02009043A publication Critical patent/MXPA02009043A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion farmaceutica para el tratamiento de la enfermedad de Parkinson que comprende L-DOPA y por lo menos un compuesto con la capacidad para bloquear la trayectoria de transferencia hacia fuera de la celula L-DOPA renal; siendo elegido dicho compuesto bloqueador entre (a) un derivado flavonoide de fenil benzopirano; (b) un derivado trans-estilbeno; o (c) floretino [3-(4-hidroxifenil)-1-(2,4,6-trihidroxifeniI)-1-propanona]. La composicion puede comprender tambien un inhibidor de la descarboxilasa de la enzima del aminoacido (AADC), tal como carbidopa o benserazida, y/o un inhibidor de la catecol-O-metil tranferasa (COMT), tal como entacapona o tolcapona. La composicion es administrada de preferencia en forma solida y la L-DOPA puede ser administrada simultaneamente o en secuencia con el compuesto bloqueador de la transferencia hacia fuera de la celula L-DOPA renal.
MXPA02009043A 2000-03-14 2001-03-13 Composiciones que comprenden bloqueadores de la transferencia de la celula l-dopa renal para el tratamiento de la enfermedad de parkinson. MXPA02009043A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0006063A GB2348371B (en) 2000-03-14 2000-03-14 Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
PCT/EP2001/002896 WO2001068065A2 (en) 2000-03-14 2001-03-13 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
MXPA02009043A true MXPA02009043A (es) 2004-08-19

Family

ID=9887552

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009043A MXPA02009043A (es) 2000-03-14 2001-03-13 Composiciones que comprenden bloqueadores de la transferencia de la celula l-dopa renal para el tratamiento de la enfermedad de parkinson.

Country Status (23)

Country Link
US (1) US20040242503A1 (es)
EP (1) EP1267853B1 (es)
JP (1) JP3677002B2 (es)
KR (1) KR100738746B1 (es)
CN (1) CN1262269C (es)
AR (1) AR035567A1 (es)
AT (1) ATE275397T1 (es)
AU (1) AU781280B2 (es)
BR (1) BR0109220A (es)
CA (1) CA2402712C (es)
CZ (1) CZ297123B6 (es)
DE (1) DE60105401T2 (es)
DK (1) DK1267853T3 (es)
ES (1) ES2228858T3 (es)
GB (1) GB2348371B (es)
HU (1) HUP0300130A3 (es)
MX (1) MXPA02009043A (es)
PL (1) PL359327A1 (es)
PT (1) PT1267853E (es)
RU (1) RU2266111C2 (es)
SI (1) SI1267853T1 (es)
TR (1) TR200402661T4 (es)
WO (1) WO2001068065A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US7381772B2 (en) * 2003-12-12 2008-06-03 E. I. Du Pont De Nemours And Company Toughened poly(lactic acid) compositions
ES2390126T3 (es) * 2004-06-04 2012-11-06 Xenoport, Inc. Derivados de levodopa, y composicones y usos de la misma
EP1781094B1 (en) * 2004-07-07 2016-04-27 Kampavata AB Transgenic non-human animal for use in research models for studying parkinson's disease
RU2431634C2 (ru) * 2005-03-11 2011-10-20 Говард Флори Инститьют Оф Експериментл Физиолоджи Энд Медсин Соединения флавоноидов и их применение
GB0505756D0 (en) * 2005-03-21 2005-04-27 Mars Uk Ltd Method
US20090012170A1 (en) * 2005-09-21 2009-01-08 Helena Nissinen Treatment of symptoms of motor dysfunction
EP1957109A2 (en) * 2005-12-02 2008-08-20 Sirtris Pharmaceuticals, Inc. Modulators of cdc2-like kinases (clks) and methods of use thereof
TWI403493B (zh) 2005-12-05 2013-08-01 Xenoport Inc 左旋多巴前藥的甲磺酸鹽，其組成物，及其用途
US7829592B2 (en) 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
TW200843732A (en) 2006-12-21 2008-11-16 Xenoport Inc Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
AU2008257437A1 (en) * 2007-02-14 2008-12-04 Mars, Incorporated Neurogenic compounds
BRPI0801239A2 (pt) * 2008-04-01 2009-11-17 Ache Lab Farmaceuticos Sa uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
EP2349973A2 (en) 2008-10-20 2011-08-03 XenoPort, Inc. Methods of synthesizing a levodopa ester prodrug
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
CN105902535A (zh) * 2009-04-13 2016-08-31 中国医学科学院药物研究所 黄芩素在制备预防和治疗帕金森病药物中的应用
RU2537137C2 (ru) 2009-11-09 2014-12-27 Ксенопорт, Инк. Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения
CN101797243B (zh) * 2010-03-23 2012-01-18 广东药学院 一种含有左旋多巴和冰片的组合物及其应用
KR101327936B1 (ko) * 2011-07-06 2013-11-13 한국식품연구원 옥시레스베라트롤 이민 유도체를 유효성분으로 함유하는 뇌신경보호 효과를 가지는 조성물
CN102755312A (zh) * 2012-07-16 2012-10-31 中国科学院大连化学物理研究所 具有黄酮骨架结构的化合物作为帕金森症治疗药物的应用
GB201302755D0 (en) 2013-02-15 2013-04-03 Mars Inc Horse supplement
CN103211832A (zh) * 2013-04-24 2013-07-24 无锡艾德美特生物科技有限公司 含杨酶苷或/和杨梅素的药物组合物及其在制备帕金森治疗药物中的用途
CN104116730A (zh) * 2013-04-26 2014-10-29 中国科学院大连化学物理研究所 二氢杨梅素作为活性成份在制备帕金森症治疗药物中的应用
KR101583399B1 (ko) * 2013-10-22 2016-01-08 충북대학교 산학협력단 아사리닌 또는 (-)-세사민을 함유하는 파킨슨병 예방 또는 치료용 약학조성물
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
KR102681552B1 (ko) * 2016-09-27 2024-07-04 (주)아모레퍼시픽 소장 상피세포에서의 카테킨 흡수 증진제
CN111329853A (zh) * 2020-04-21 2020-06-26 遵义医科大学 一种治疗帕金森病的药物组合物及其应用和治疗帕金森病的药物
CN116908319A (zh) * 2023-05-31 2023-10-20 苏州和合医学检验有限公司 一种检测血液中苄丝肼浓度的方法
CN119192117B (zh) * 2024-10-31 2025-09-26 贵州医科大学 一种从马尾松松塔内分离出的黄酮类化合物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) * 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
JPS6450877A (en) * 1987-08-20 1989-02-27 Ichimaru Pharcos Inc Oxygen radical catching and removing agent
JPH035423A (ja) * 1989-06-01 1991-01-11 Ichimaru Pharcos Co Ltd フラボノイド含有過酸化脂質生成抑制剤
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
JPH09241637A (ja) * 1996-03-14 1997-09-16 Chugai Pharmaceut Co Ltd 活性酸素ラジカル除去用組成物およびその方法
GB9702310D0 (en) * 1997-02-05 1997-03-26 Univ Hertfordshire Invention
US6537969B1 (en) * 1997-10-24 2003-03-25 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
JPH11323326A (ja) * 1998-02-06 1999-11-26 Nagaoka Koryo Kk 活性酸素消去剤、皮膚保全剤および変色防止剤
FR2787319B1 (fr) * 1998-12-22 2002-06-14 Oreal Utilisation d'hydroxystilbenes pour la teinture, composition prete a l'emploi les contenant et procede de teinture
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
CN101822676A (zh) * 2002-01-28 2010-09-08 协和发酵麒麟株式会社 治疗运动疾病患者的方法

Also Published As

Publication number Publication date
EP1267853B1 (en) 2004-09-08
ES2228858T3 (es) 2005-04-16
SI1267853T1 (en) 2005-04-30
DE60105401D1 (de) 2004-10-14
JP2003526658A (ja) 2003-09-09
ATE275397T1 (de) 2004-09-15
CZ20023348A3 (cs) 2003-02-12
AU781280B2 (en) 2005-05-12
JP3677002B2 (ja) 2005-07-27
DE60105401T2 (de) 2005-10-13
CN1262269C (zh) 2006-07-05
RU2266111C2 (ru) 2005-12-20
AU5828301A (en) 2001-09-24
CN1429109A (zh) 2003-07-09
PL359327A1 (en) 2004-08-23
TR200402661T4 (tr) 2004-11-22
PT1267853E (pt) 2004-12-31
KR20030095184A (ko) 2003-12-18
HUP0300130A2 (en) 2003-05-28
EP1267853A2 (en) 2003-01-02
US20040242503A1 (en) 2004-12-02
GB2348371A (en) 2000-10-04
AR035567A1 (es) 2004-06-16
CA2402712C (en) 2005-05-17
KR100738746B1 (ko) 2007-07-12
BR0109220A (pt) 2003-03-18
CA2402712A1 (en) 2001-09-20
GB0006063D0 (en) 2000-05-03
WO2001068065A2 (en) 2001-09-20
WO2001068065A9 (en) 2002-07-18
WO2001068065A3 (en) 2002-02-21
GB2348371B (en) 2001-04-04
CZ297123B6 (cs) 2006-09-13
DK1267853T3 (da) 2005-01-10
HUP0300130A3 (en) 2005-11-28

Similar Documents

Publication Publication Date Title
MXPA02009043A (es) Composiciones que comprenden bloqueadores de la transferencia de la celula l-dopa renal para el tratamiento de la enfermedad de parkinson.
ES2192227T3 (es) Composiciones farmaceuticas orales con liberacion retardada de inhibidores reversibles de las bombas de protones.
IS2749B (is) Ný tegund af lyfjablöndu
TW200505423A (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
WO2002058698A3 (en) Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
WO2005027850A3 (en) Treating or preventing restless legs syndrome using prodrugs of gaba analogs
AU2003293555A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2002064136A3 (en) Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
WO2000053149A3 (en) Method and composition for administering a cyclooxygenase-2 inhibitor
WO2003045334A3 (en) Methods and compositions for ameliorating the undesirable effects of chemotherapy
WO2002102345A3 (fr) Deferoxamine comme inhibiteur de no-synthase et utilisations
PT965351E (pt) Composicao para alimentos dieteticos e metodo dietetico utilizando este tipo de composicao
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
DK1196174T3 (da) Diætmæssigt calcium, som et tilskud til D-vitamin-forbindelsesbehandling af multipel sclerose
MXPA04001779A (es) Modulacion de almacenamiento de vitamina.
BR0313177A (pt) Administração oral de calcitonina
DK1441708T3 (da) Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme
PL377584A1 (pl) Deuterowane pochodne katecholoaminy oraz środki lecznicze zawierające te związki
PT1007034E (pt) Combinacoes que contem bergamotina para aumentar a biodisponibilidade oral de agentes farmaceuticos
BR0207446A (pt) Composição medicinal que contém diclofenaco e ornoprostil.
WO2005020954A3 (en) Proton pump inhibitor formulations, and methods of preparing and using such formulations
IT1317042B1 (it) Fumarati doppi di una carnitina e creatina, e integratori alimentari,dietetici e farmaci che li contengono.
NZ336043A (en) Use of COMT inhibitors for preventing diabetic vascular dysfunctions or neuropathy
MXPA03005384A (es) Composiciones framaceuticas de un inhibidor de bomba de proton revestido no enterico con una combinacion de sal de bicarbonato y sal de carbonato.
EP0974351A3 (en) Medicament for preventing and treating gastrointestinal damage

Legal Events

Date Code Title Description
FG Grant or registration